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ABSTRACT  25 
Bacterial membrane vesicles research has so far mainly focussed on Gram-negative bacteria. 26 
Only recently Gram-positive bacteria have been demonstrated to produce and release 27 
extracellular membrane vesicles (MVs) that contribute to bacterial virulence. Although 28 
treatment of bacteria with antibiotics is a well-established trigger of bacterial MVs 29 
formation, the underlying mechanisms are poorly understood. In this study we show that 30 
antibiotics can induce MVs through different routes in the important human pathogen 31 
Staphylococcus aureus. DNA damaging agents and antibiotics inducing the SOS response 32 
triggered vesicle formation in lysogenic strains of S. aureus but not in their phage-devoid 33 
counterparts. β-lactam antibiotics flucloxacillin and ceftaroline increased vesicle formation 34 
in a prophage-independent manner by weakening the peptidoglycan layer. We present 35 
evidence that the amount of DNA associated with MVs formed by phage lysis is higher than 36 
that of MVs formed by β-lactam antibiotics-induced blebbing. The purified MVs derived 37 
from S. aureus protected the bacteria from challenge with daptomycin, a membrane-38 
targeting antibiotic, both in vitro and ex vivo in whole blood. In addition, the MVs protected 39 
S. aureus from killing in whole blood, indicating that antibiotic-induced MVs function as a 40 
decoy and thereby contribute to the survival of the bacterium.  41 
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INTRODUCTION 42 
Bacterial membrane vesicles (MVs) affect diverse biological processes, including virulence, 43 
DNA transfer, export of cellular metabolites, phage decoy and cell-to-cell communication, as 44 
shown in various bacterial species (1-3). Although MVs were originally shown to originate 45 
from blebbing of the outer membrane of Gram-negative bacteria, evidence has 46 
accumulated that various Gram-positive bacteria also release MVs composed of cytoplasmic 47 
membrane (2). A recent study has shown that MVs formation in the Gram-positive 48 
bacterium Bacillus subtilis is stimulated by the expression of an endolysin, which is encoded 49 
by a defective prophage (4). The hydrolytic activity of the endolysin creates small holes in 50 
the peptidoglycan layer through which cytoplasmic membrane (CM) material can protrude 51 
and is released as cytoplasmic MVs (CMVs). It has been observed that these cells lose CM 52 
integrity as indicated by the formation of ghost cells containing many intracellular CMVs. 53 
Therefore, this vesicle biogenesis mechanism has been named “bubbling cell death” 54 
(Masanori Toyofuku, Nobuhiko Nomura, Leo Eberl “Types and origins of bacterial 55 
membrane vesicles” Nature Reviews Microbiology, doi:10.1038/s41579-018-0112-2, in 56 
press). 57 
Prophages are integrated in the bacterial host genome and are passed on to daughter cells 58 
at each cell division. When the host cell experiences genotoxic stress, e.g. by exposure to 59 
DNA damaging agents or UV radiation, the prophage induces the expression of lytic genes 60 
that promote DNA replication, phage particle assembly, DNA packaging, and eventually 61 
bacterial lysis to release the new phage particles along with vesicles that are also formed in 62 
this process (4). Another route that stimulates CMVs formation through the weakening of 63 
the cell wall is the treatment with β-lactam antibiotics (4-6), which leads to protrusion of the 64 
cytoplasmic membrane into the extracellular space. While it is well known that MVs 65 
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formation is stimulated by antibiotic treatment, the underlying mechanisms are only poorly 66 
understood.  67 
Staphylococcus aureus (S. aureus) causes a wide spectrum of human infections, ranging 68 
from superficial cutaneous infections to systemic infections, including pneumonia, 69 
osteomyelitis, endocarditis, and bacteremia (7). The production of CMVs plays an important 70 
role in the delivery of S. aureus virulence factors into eukaryotic host cells (8, 9), stimulates 71 
biofilm formation (10), increases the resistance to killing by whole blood and activates 72 
purified human neutrophils ex vivo. Mice previously immunized with CMVs were protected 73 
against subcutaneous and systemic S. aureus infection (11). CMVs were also shown to 74 
increase antibiotic resistance, as they can contain β-lactamases (12). Here we used lysogenic 75 
S. aureus strains and their phage-devoid counterparts to investigate the effect of different 76 
antibiotics on CMVs formation. Our results show that antibiotics can induce vesiculation by 77 
at least two routes, in a phage-dependent as well as phage-independent fashion, depending 78 
on the mode of action of the antibiotic compound. We further examined how the different 79 
routes resulting in CMVs production influence the content of the CMVs as well as their 80 
efficacy in protecting against antibiotic killing.  81 
 82 
RESULTS 83 
To test whether temperate phages affect vesicle formation in S. aureus we compared the 84 
amounts of CMVs produced by the MSSA clinical strains NRS135 and RN4220 and their 85 
phage-bearing counterparts NRS77phage and RN4220phage, respectively (Tab. 1). Under 86 
standard growth conditions, no significant difference in CMVs production was observed (Fig. 87 
1). However, upon treatment with bacterial growth subinhibitory concentrations of the DNA 88 
damaging agent mitomycin C (MMC), a well characterized trigger of the SOS response (13), a 89 
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strong increase in CMVs formation was observed in the strains carrying a prophage but not 90 
in the cured strains devoid of phages (Fig. 1A). Moreover, CMVs formation was stimulated in 91 
a concentration-dependent manner in the lysogenic strains (Fig. 1B). Using transmission 92 
electron microscopy we observed CMVs, phages and ghost cells, indicative of endolysin-93 
triggered cell lysis, in samples of the MMC-treated, phage-carrying strains (Fig. 2A, C and E). 94 
Ghost cells were rarely observed in untreated controls (Fig. 2F) or cured strains. These data 95 
suggest that phage-triggered cell lysis is an important mechanism of CMVs formation in S. 96 
aureus.  97 
As some antibiotics, particularly quinolones, are known to induce the cellular SOS response 98 
(14, 15), we tested next whether treatment with ¼ or 10 times the minimal inhibitory 99 
concentration (MIC) of ciprofloxacin (CIP) would affect CMVs production. In the lysogenic 100 
strain NRS77phage but not in the phage-free background strain NRS135 we observed a clear 101 
increase in vesicles production (Fig. 3A and C). With strain RN4220 we observed a similar 102 
trend at MIC ¼, while the differences were not statistically significant for MIC10 (Fig. 3B and 103 
D). 104 
Another possibility to stimulate vesicle formation in Gram-positive bacteria is to inhibit cell 105 
wall biosynthesis with β-lactam antibiotics (4-6). Treatment with β-lactam antibiotics is 106 
thought to weaken the peptidoglycan such that cytoplasmic membrane material can 107 
protrude into the extracellular space and is released as CMVs. Exposing the S. aureus strains 108 
to 10 times the MIC of the β-lactam antibiotics flucloxacillin (FLU) or ceftaroline (CPT) 109 
strongly increased vesicle formation independent of the presence or absence of the 110 
prophage (Fig. 3C and D). When exposed to ¼ the MIC of the antibiotics, a clear, phage-111 
independent effect was observed for CPT but not for FLU, which at this low concentration 112 
caused a modest increase of vesiculation only in the lysogenic strain NRS77phage (Fig. 3A and 113 
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B). While TEM micrographs showed large amounts of CMVs, phages could not be observed 114 
when bacteria were treated with 10 times the MIC of FLU (Fig. 2B), indicating that these 115 
vesicles do not originate from SOS-induced bubbling cell death but likely through an 116 
alternative blebbing mechanism (Fig. 2D).  117 
To investigate whether the cargo carried by CMVs originating from blebbing or SOS-induced 118 
cell lysis are different, we determined the amount of DNA associated with the CMVs (Fig. 119 
4A). These data provided clear evidence that CMVs originating from phage lysis have a 120 
generally higher DNA content than CMVs originating from a blebbing mechanism. 121 
We next tested whether S. aureus CMVs can protect cells from the last-resort antibiotic 122 
daptomycin (DAP), which inhibits cell envelope synthesis by interfering with fluid membrane 123 
microdomains (16). Due to its intrinsic resistance to infection with the phages produced by 124 
RN4220phage and NRS77phage strains, the clinical S. aureus strain CI1449, a bloodstream 125 
isolate recovered from a patient with S. aureus endocarditis, was chosen. Incubation of the 126 
CI1449 strain with a phage lysate obtained from the NRS77phage strain did not result in phage 127 
binding to the bacterial surface (Fig. S1C and D), while binding of phages was observed for 128 
strain NRS135 (Fig. S1A and B), indicating that strain Cl1449 lacks a functional phage 129 
receptor. This allowed us to test the protective effect of MMC-induced CMVs as they co-130 
purified with phages (Fig. 2A), which would lyse sensitive strains. We assessed DAP killing in 131 
the presence or absence of purified CMVs both in vitro as well as ex vivo using freshly-drawn 132 
human whole blood.  133 
For the in vitro experiments exponentially growing phage-resistant S. aureus strain CI1449 134 
(5*107 CFUs, high inoculum; and 105 CFUs, low inoculum) were challenged with two 135 
different concentrations of CMVs. FLU-induced CMVs exhibited a clear concentration-136 
dependent protective effect against DAP as early as 30 minutes after the start of the assay 137 
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for both inocula size tested (Fig. 5C and D). Although slightly reduced, a protective effect 138 
was also observed for MMC-induced CMVs (Fig. 5A and B). For the ex vivo experiments 139 
2.3*104 S. aureus CI1449 cells were suspended in whole blood and CMVs and DAP were 140 
added (either separately or after pre-incubation for 30 minutes in whole blood). Pre-141 
incubation resulted in an enhanced protective effect against DAP challenge, which was 142 
observed as early as 15 minutes after the start of the assay for both MMC and FLU-induced 143 
CMVs (Fig. 6A and B). Without pre-incubation the protective effect was slightly reduced.  144 
We also observed a significant protective effect of CMVs against whole blood killing for both 145 
MMC and FLU-induced CMVs after 120 minutes of incubation, confirming that CMVs can 146 
also protect against the host’s innate immune system (Fig. 6C and D). In agreement with the 147 
in vitro data, the level of protection conferred by MMC-induced CMVs ex vivo was lower 148 
than by FLU-induced CMVs.  149 
 150 
DISCUSSION 151 
This study demonstrates that treatment of S. aureus with the DNA damaging agent MMC or 152 
specific antibiotics routinely used in clinics increases CMVs production both in a phage-153 
dependent as well as phage-independent fashion, depending on the mode of action of the 154 
compounds. We provide evidence that at least two different mechanisms account for this 155 
stimulatory effect: MMC and CIP induce the SOS response and consequently increase vesicle 156 
formation through endolysin-triggered cell death, provided the strain harbors a temperate 157 
phage. On the other hand, the β-lactams FLU and CPT, at 10 times MIC, weaken the cell wall 158 
and thereby stimulate CMVs production through a phage-independent blebbing mechanism. 159 
A significant induction of vesiculation was observed already at ¼ MIC of CPT, while this low 160 
concentration of FLU only weakly increased vesicle formation in the lysogenic strain 161 
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NRS77phage. No difference in CMVs production was observed for untreated strains, 162 
independently of the presence of prophages. This is in agreement with a recent study 163 
showing that under non-inducing growth conditions, phage-encoded endolysins are not 164 
essential for CMVs formation which, however, depends on the host’s autolysin Sle1 (13, 17).  165 
We also observed a difference in the DNA cargo harbored by CMVs produced by strains 166 
NRS135 and NRS77phage after stimulation with the DNA damaging agents MMC and CIP. This 167 
difference possibly occurs because the phage lytic cycle involves the degradation of the host 168 
chromosome resulting in smaller DNA fragments that may be more efficiently packed into 169 
vesicles. This idea is supported by a recent report showing that treatment of 170 
Stenotrophomonas maltophilia with CIP not only stimulates the production of high content 171 
DNA MVs but also of large numbers of phages, which are both a consequence of SOS 172 
response induction in this bacterium (18). In contrast, no significant difference in DNA load 173 
was observed between lysogenic and cured strains for CMVs produced by induction with the 174 
cell membrane-damaging agents FLU and CPT.  175 
Previous work has shown that CMVs can provide protection against host defence factors 176 
such as antimicrobial peptides from mammalian tissue and complement system factors of 177 
the blood (19-21). In addition, it was recently shown that vesicles can serve as decoys for 178 
phages and membrane-targeting antibiotics (22, 23). In agreement with this study, we show 179 
that both FLU- and MMC-induced CMVs protect cells from the membrane-active antibiotic 180 
DAP not only in vitro but also ex vivo in whole blood. This result suggests that the protective 181 
effect is relevant in a more physiological condition, which may more closely reflect the 182 
situation of an infected patient. The lower degree of protection we observed for MMC-183 
induced CMVs in the bacterial protection assay, as compared to FLU-induced CMVs, could 184 
be due to the fact that CMVs induced by the SOS-response activation carry phage endolysins 185 
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that can affect cell viability (4, 24, 25). Askarian et al. recently showed that CMVs naturally 186 
produced by S. aureus protect cells from whole blood killing (11). We observed a similar 187 
effect for CMVs produced by S. aureus in response to DNA damage or antibiotic stress, 188 
suggesting that the mechanism of CMV genesis does not affect the protective function of 189 
CMVs against the host innate immune defence (11). As phage binding to the surface of 190 
strain CI1449 is impaired, the presence of phages in MMC-induced CMVs preparations is not 191 
responsible for the protective effect observed towards DAP and whole blood killing. 192 
The setup we used in this study aimed to reflect the clinical situation. S. aureus infections 193 
due to methicillin susceptible S. aureus are typically treated with FLU alone or in 194 
combination with a fluoroquinolone such as CIP, which leads to CMVs release as shown in 195 
our study. DAP is used for treating multi-resistant S. aureus strains infections, including 196 
MRSA strains. In addition, DAP may be added to FLU in case of persisting bacteremia. Our 197 
data show that antibiotic-induced CMVs could hinder the action of DAP against S. aureus 198 
and thus may counteract the clearance of the infection. Interestingly, a recent study showed 199 
that DAP can trigger the release of membrane vesicles in S. aureus, which may protect the 200 
bacterial cells (26). Further work will be required to unravel the differences between DAP- 201 
and FLU-triggered CMVs that account for their varied DAP binding affinities. 202 
 203 
MATERIAL AND METHODS 204 
 205 
Strains and media 206 
S. aureus strains (Tab.1) were grown in LB Lennox (BD) shaking (220 rpm) at 37°C in the 207 
presence of MMC (10, 50, 100 or 150 ng/ml) or DAP (Cubicin), CIP (Ciproxin), FLU 208 
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(Floxapen), CPT (Zinforo) at an MIC of ¼, 2.3 or 10, depending on the assay (for MIC values 209 
see Tab.1).  210 
The RN4220 strain was derived from strain NCTC8325-4 by UV and chemical mutagenesis 211 
(27, 28). Its prophage-positive counterpart, strain RN4220phage, was created by phage 212 
transduction using S. aureus MRSA bacteremia strain 300-169 (29) as prophage donor. To 213 
obtain phage preparations, cultures of strain 300-169 were treated with mitomycin C at a 214 
concentration of 0.5 μg/ml, as previously described (30). The filtered supernatants 215 
corresponding to putative lysates were stored at −80°C before utilization. Phages were 216 
propagated using the receiver isolate RN4220. Selection was performed by PCR as 217 
prophages are devoid of any resistance markers (Tab. 2). Titrated phage preparations were 218 
kept at -80°C. The induced phage preparations were centrifuged on a sucrose density 219 
gradient. Phage particles were negatively stained with 2% uranyl acetate, examined in a 220 
JEOL 1230 transmission electron microscope at an accelerating voltage of 120 kV, and 221 
photographed (31). Morphological types were defined on the basis of phage tail length. The 222 
NRS77 strain (depicted as NRS77phage in this work) was cured from phages to give rise to 223 
strain NRS135 (32, 33). CI1449 is an invasive S. aureus strain isolated at the University 224 
Hospital Zurich. It was chosen for bacterial protection and whole blood killing assays due to 225 
the fact that it is a blood stream isolate as well as its resistance to infection by the phages 226 
harbored in NRS77phage and RN4220phage strains, as confirmed by plaque assay. MIC values 227 
were determined using the broth microdilution test in LB medium, as previously described 228 
(34). 229 
 230 
CMVs induction and quantification 231 
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S. aureus was grown overnight (O/N) in 10 ml of LB Lennox in a 50 ml tube with shaking at 232 
220 rpm, diluted in 10 ml of fresh medium in a 50 ml tube to an OD600nm of 0.1 and then 233 
cultured in the presence or absence of MMC for 4h or antibiotics for 6h. CMVs were isolated 234 
and quantified as previously described (35). Briefly, cell cultures were centrifuged for 10 min 235 
at 4,600 g and the supernatant was filtered through a 0.22 μm pore size filter and 236 
ultracentrifuged for 1h at 150,000 g at 4°C. The resulting pellets were resuspended in 237 
double distilled water for CMVs quantification by staining with the FM1-43 fluorescent dye 238 
(Life Technologies, USA). Fluorescence was evaluated by using a Varioscan flash fluorimeter 239 
(Thermo Scientifc) or a Synergy HT plate reader (MWG Biotech). Protein content of CMVs 240 
preparations was assessed using the BCA protein assay kit (Thermo Scientific). In our 241 
system, a value of 1,500 AU corresponds to a CMVs preparation of 250 μg protein/ml. 242 
 243 
Transmission electron microscopy 244 
CMVs were isolated from bacterial cultures stimulated with either 100 ng/ml MMC or MIC 245 
10 of FLU as described above. The isolated CMVs were absorbed on glow-discharged 246 
Formvar-coated 300-mesh copper grids and negatively stained with 1% uranyl acetate for 247 
visualisation. Bacteria thin sections were prepared as previously described (36) from 248 
bacterial cultures stimulated with either 100 ng/ml MMC or MIC 10 of FLU. 249 
 250 
DNA content measurement 251 
The DNA load of CMVs derived from NRS135 and NRS77phage strains stimulated with either 252 
100 ng/ml MMC or MIC 10 of antibiotics was quantified as previously described (37) with 253 
some minor modifications. Briefly, CMVs were resuspended in PBS and incubated for 1h in 254 
the presence of DNase I (NEB) to degrade extravesicular DNA. The DNase was then 255 
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inactivated at 75C° for 15 min. DNA was released from CMVs by lysis, using 0.125% Triton X-256 
100. The quantification of DNA was carried out using the PicoGreen dsDNA kit (Invitrogen) 257 
and was normalized against CMVs concentrations. 258 
 259 
Bacterial protection assay 260 
CMVs derived from either MMC (100 ng/ml) or FLU (MIC 10)-stimulated NRS77 bacteria 261 
were incubated with DAP (MIC 10) for 2h in LB Lennox at a final concentration of 62.5 or 262 
31.25 μg protein/ml. A CI1449 O/N culture was diluted 1:10 in fresh LB and grown for 2h, 263 
diluted to an OD600nm of 0.2 in LB+CaCl2 (50 μg/ml final concentration) and added at 5*10
7 264 
(high inoculum) or 105 (low inoculum) colony forming units (CFUs)/ml to the CMVs-DAP mix. 265 
CFUs counts were determined at 30 min, 1h, 2h, 3h, 4h, 6h and 24h. 266 
 267 
Whole blood killing 268 
To assess the role of CMVs in protecting bacteria from whole blood killing and DAP 269 
challenge in whole blood we used two experimental setups. CMVs and DAP where either 270 
pre-incubated in 400 μl of freshly-drawn blood for 30 minutes at 37°C prior to addition of 271 
bacteria (DAP+CMVs-pre) or added to 400 μl of freshly-drawn blood at the same time as the 272 
bacteria (DAP+CMVs). The CMVs used for this assay were derived from NRS77 cultures, 273 
which were either stimulated with MMC (100 ng/ml) or FLU (MIC 10). CMVs were used at a 274 
final concentration of 14.4 ug protein/ml and DAP was used at an MIC of 2.3.  275 
CI1449 strain was prepared as described for the bacterial protection and added to whole 276 
blood to a concentration of 2.3*104 CFUs/ml. Bacterial survival was assessed at 15, 30, 60 277 
and 120 minutes by spotting bacterial suspensions of serial dilutions on TSB agar plates. 278 
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Bacteria were enumerated after O/N growth at 37°C. Blood was drawn in heparin tubes 279 
(BD).  280 
 281 
Phage lysates 282 
Lysates of phages carried by the NRS77 strain were prepared as follows. 100 μl of a CMV 283 
sample obtained by stimulation of the NRS77 strain with 100ng/ml MMC were added to 300 284 
μl of an O/N culture of the recipient strain NRS135 after addition of 5mM CaCl2 to the 285 
growth medium. Following incubation for 15 minutes at room temperature, 3 ml of warm LB 286 
soft agar (LB + 0.6% agar) was added and samples were spread on 5% sheep blood plates 287 
(Biomerieux). The plates were incubated O/N at 37°C and the phage lysate was harvested in 288 
2 ml LB + 5mM CaCl2 and stored at 4°C after filtration through a 0.45 μm filter. 289 
 290 
Phage binding assay 291 
100 μl of phage lysates were incubated with300 μl of an O/N culture of the recipient strains 292 
NRS135 and CI1449, after the addition of 5mM CaCl2 to the growth medium. Bacteria were 293 
incubated for 15 minutes at room temperature and subsequently washed once in PBS and 294 
resuspended in 2.5% glutaraldehyde in 0.1 mM cacodylate buffer. Samples were processed 295 
for electron microscopy as described above. 296 
  297 
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Study approval 298 
Collection of healthy volunteers’ blood complied with the current version of the Declaration 299 
of Helsinki. The national legal and regulatory requirements and sample collection was 300 
approved by the Canton Ethics Committee (Kantonale Ethikkommission Zurich, Switzerland, 301 
KEK---2010---0126).  302 
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FIGURE LEGENDS 431 
 432 
Fig. 1. MMC treatment induces CMVs formation in lysogenic S. aureus strains NRS and 433 
RN4220. Mitomycin C (MMC) was added at 100 ng/ml (A) and at the concentrations 434 
indicated (B) to log phase bacterial cultures of strains NRS135 and RN4220, as well as their 435 
lysogenic variants NRS77phage and RN4220phage. After 4 hours of incubation, the amount of 436 
CMVs in the supernatants was measured using a fluorescent dye and quantified in arbitrary 437 
units (AU). In our system, a value of 1,500 AU corresponds to a CMVs preparation containing 438 
250 ug protein/ml. The graphs show data from at least three independent experiments. 439 
Statistical analysis was carried out using the unpaired t-test. *=p<0.05; **=p<0.01; 440 
***=p<0.001; ****=p<0.0001. 441 
 442 
Fig. 2. TEM images of membrane vesicles and S. aureus after stimulation with MMC or 443 
FLU. CMVs and cells TEM micrographs of S. aureus RN4220phage and NRS77phage treated with 444 
either 100ng/ml MMC (A, C, E) or 10 times the MIC of FLU (B, D). Phages are indicated by 445 
dashed arrows. In samples of MMC-treated cultures the presence of ghost cells (C) 446 
(depicted by arrows and enlargement on upper right panel) and of phages (E) was observed. 447 
(D) In cultures treated with FLU, a high number of ghost cells and cells with blebs (indicated 448 
by arrows and in the enlargement on upper right panel) were observed. (F) Untreated 449 
RN4220phage cells. 450 
 451 
Fig. 3. Antibiotics triggered phage-dependent and independent CMVs induction in S. 452 
aureus NRS and RN4220 strains. Log phase cultures of strains NRS135 and RN4220 as well 453 
as their lysogenic variants NRS77phage and RN4220phage were treated with ciprofloxacin (CIP), 454 
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flucloxacillin (FLU) and ceftaroline (CPT) at an MIC of ¼ (A, B) or at an MIC of 10 (C, D). The 455 
amount of CMVs in the supernatants was measured after 6 hours induction using a 456 
fluorescent dye and quantified in arbitrary units (AU). In our system, a value of 1,500 AU 457 
corresponds to a CMVs preparation containing 250 ug protein/ml. The graphs show data 458 
from at least three independent experiments. Statistical analysis was carried out using the 459 
unpaired t-test. *=p<0.05; **=p<0.01; ***=p<0.001; ****=p<0.0001. 460 
 461 
Fig. 4. Amounts of DNA associated with CMVs. (A) The DNA content of CMVs isolated from 462 
S. aureus NRS135 and NRS77phage cultures treated with either 100 ng/ml MMC or MIC 10 of 463 
the indicated antibiotics was determined. The graphs show data from at least three 464 
independent experiments. Statistical analysis was carried out using the unpaired t-test; 465 
***=p<0.001; ns=not significant. 466 
 467 
Fig. 5. CMVs derived from S. aureus NRS77phage stimulated with MMC or FLU protect a 468 
clinical S. aureus strain from DAP treatment. Log phase cultures of the clinical S. aureus 469 
isolate CI1449 were treated with 10 times the MIC of DAP in the presence or absence of two 470 
different concentrations of CMVs (62.5 or 31.25 μg protein/ml) derived from S. aureus 471 
NRS77phage stimulated with (A, B) MMC (100 ng/ml) or (C, D) FLU (MIC 10). Viability of the S. 472 
aureus clinical isolate CI1449 was followed over 24 hours. Strain CI1449 is resistant to 473 
infection by phages produced by strain NRS77phage upon treatment with MMC. High 474 
inoculum: 5*107 CFUs/ml; low inoculum: 105 CFUs/ml. Missing data points indicate no 475 
detectable live bacteria; the lower detection limit for this assay is 103 CFUs/ml. The graphs 476 
show data from at least three independent experiments.  477 
 478 
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Fig. 6. CMVs derived from S. aureus NRS77phage stimulated with MMC or FLU protect a 479 
clinical S. aureus strain from daptomycin killing in whole blood and from whole blood 480 
killing. 2.3*104 CFUs/ml of the clinical S. aureus isolate CI1449 were incubated in 400 μl 481 
blood in the presence or absence of DAP (MIC 10) and/or CMVs (14.4 μg protein/ml) derived 482 
from either MMC (A and C) or FLU (B and D). Data from at least three independent 483 
experiments are shown. Statistical analysis was carried out using the unpaired t-test. Results 484 
of statistical analysis are indicated on the graphs. *=p<0.05; **=p<0.01; ***=p<0.001; 485 
****=p<0.0001; ns=not significant. 486 
  487 
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TABLES 488 
 489 
  MIC (ug/ml) 
S. aureus 
strain 
Reference MMC DAP CIP FLU CPT 
RN4220phage (27-29) P. François laboratory 0.125 4 0.50 0.0625 4 
RN4220 (27, 28) 0.500 2 0.25 0.0625 4 
NRS77phage (32, 33) 0.250 4 0.25 0.0625 4 
NRS135 (32, 33) 0.500 4 0.50 0.1250 4 
CI1449 A. Zinkernagel laboratory NA 2 NA NA NA 
 490 
Table 1 – S. aureus strains and MICs - All strains were grown in LB Lennox broth (BD) at 37°C 491 
aerobically under constant shaking at 220 rpm or plated on Tryptic Soy Broth (TSB) agar 492 
(BD). MICs were determined in LB by broth microdilution test (34). MMC = mitomycin C; 493 
DAP = daptomycin; CIP = ciprofloxacin; FLU = flucloxacillin; CPT = ceftaroline 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
Primer name Sequence 
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F1_phageKati TCCATTGCATGTTGTCACCT 
R1_phageKati ATTTCAGCGGCTTGTTTTGT 
F2_phageKati TAAATTGGTGCGTCAGCTTG 
R2_phageKati ATCAGCATTTGATGGCGTTT 
SAM_F35 ATGACCCATGGGAAGCATAT 
SAM_R1124 GTTTGTGCATATGACGCTCA 
 502 
Table 2 – Primers used for the selection of the RN4220phage strain – The primers were used 503 
to screen for the presence of prophages in the RN4220 strain genome. 504 
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